Chest
EditorialsThe Syndrome of Combined Pulmonary Fibrosis and Emphysema
References (15)
- et al.
Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment
Respir Med
(1990) - et al.
Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature
Respir Med
(2005) - et al.
HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema
Respir Med
(2008) - et al.
Combined apical emphysema and basal fibrosis syndrome (emphysema/fibrosis syndrome): CT imaging features and pulmonary function tests
J Radiol
(2009) - et al.
Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension
Chest
(2009) - et al.
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Eur Respir J
(2005) - et al.
The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis
Respir Care
(2006)
Cited by (86)
Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality
2019, Seminars in Arthritis and RheumatismSmoking-Related Diffuse Lung Diseases
2019, Seminars in RoentgenologyCitation Excerpt :Furthermore, the link between smoking and idiopathic pulmonary fibrosis is well established with the majority of patients with idiopathic pulmonary fibrosis having a smoking history.46,47 Combined pulmonary fibrosis with emphysema (CPFE) has been described as a distinct clinicopathologic entity.48 However, given the common exposure of cigarette smoke and the ensuing direct and indirect injuries to the lung, it is not surprising that emphysema, airway injury, and fibrosis are all encountered in varying degrees of severity in some smokers.
Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?
2018, Respiratory MedicineCitation Excerpt :Patients demonstrating combined histopathology patterns of UIP and other interstitial pneumonia in the same lung (discordant UIP pattern) are known to have clinical behavior similar to that of patients with UIP on histopathology from different lobes of the same lung (concordant UIP pattern) [14]. IPF phenotypes have been described, most well recognized is Combined Pulmonary Fibrosis and Emphysema (CPFE) which has been described as a syndrome distinct from Lone-IPF [15–17]. Similarly, there has been ongoing interest in describing sarcoidosis phenotypes [18–21].
The pharmacological treatment of chronic comorbidities in COPD: mind the gap!
2018, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :It is still unclear what extent of emphysema and fibrosis is needed to distinguish the patient with combined pulmonary fibrosis and emphysema (CPFE) from patients with predominant emphysema or predominant fibrosis [68]. Relatively normal FEV1/FVC ratio, with comparably depressed FEV1 and FVC (inverse effect of hyperinflation/bronchus obstruction and restriction/airway traction due to emphysema and fibrosis, respectively) in the setting of severely impaired gas exchange should raise the suspicion of CPFE [69]. When suspected, full pulmonary function tests and chest high-resolution CT can establish the presence of CPFE syndrome.
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice
2018, American Journal of PathologyIdiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities
2018, Interstitial Lung Disease
This research was supported by Hospices Civils de Lyon, “PHRC régional 2005.”
The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).
- 1
Drs. Cottin and Cordier are affiliated with Hôpital Louis Pradel, and the Reference Center for Orphan Pulmonary Diseases.